Retatrutide Dosage Protocols from Clinical Trials Phase 2 clinical trials published in The New England Journal of Medicine in 2023 established the foundational retatrutide dosage framework [6]: Standard Retatrutide Dosing Schedule: 4 mg weekly Lower effective dose with moderate efficacy 8 mg weekly Mid-range dose with enhanced metabolic effects 12 mg weekly Maximum studied dose achieving 24.2% mean weight reduction The 12 mg dose demonstrated the most significant metabolic effects but also carried the highest incidence of gastrointestinal adverse events, with nausea reported in 60-80% of participants [7]
This type of cochlear synaptopathy, referred to as hidden hearing loss because the deficits can hide behind a normal audiogram 11 , is posited to trigger neural hyperactivity that underlies tinnitus 19,20,21 , potentially offering a valuable drug target for the development of novel tinnitus treatments
Nimitphong, H., Saetung, S., Chanprasertyotin, S., Chailurkit, L
They arent proven, evidence-backed longevity therapies